SNS812

Pan-COVID

SNS812 belong to a class of nucleic acid medicines called siRNA that uses a gene silencing mechanism (RNA interference, RNAi) to specifically cleave a highly conserved region of SARS-CoV-2 genome and thereby, inhibiting virus replication, and eliminating viruses in cells.

1. In vitro and in vivo preclinical pharmacological studies have been completed, including inhibition of Vero E6 cells and human ACE2 transgenic mice infection, cytotoxicity studies, off-target genes analysis and multi-species (mouse, rat, monkey) toxicological studies . The study results suggest that SNS812 is a candidate for anti- SARS-CoV-2 infection with low toxicity, off-target rate and immunogenicity.
2. A Phase I clinical trial was completed in the United States, and no SNS812-related adverse reactions were observed in any of the tested dose groups. The related data were published in the international medical journal Clinical and Translational Science (Clin Transl Sci. 2025 Mar 21;18(3):e70202).
3. A Phase II clinical trial was completed, and the final Clinical Study Report (CSR) has been acquired.

Vaccines and antibodies currently on the market target the most mutated viral spike protein, which is easily escaped by the virus, leading to vaccine breakthroughs and repeated outbreaks of epidemics. SNS812 targets highly-conserved regions of the virus, and is expected to solve the problems of SARS-CoV-2 variants.

According to the statistics of market analysis agencies, the COVID-19 preventive and therapeutic drug market is 150 billion (IQVIA Holdings) and 25.6 billion US dollars (IncInsightAce Analytic) respectively. SNS812 is currently one of the few drug candidates in the world that can target broad-spectrum of SARS-COV-2 variants.